<DOC>
	<DOCNO>NCT01333332</DOCNO>
	<brief_summary>The purpose study determine safety obtain preliminary estimate rate major pathologic response neoadjuvant accelerate fraction , standard dose radiation give chemotherapy patient locally advanced pancreas cancer .</brief_summary>
	<brief_title>Radiotherapy With Chemotherapy Neoadjuvant Therapy Resectable Borderline Resectable Pancreas Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Inclusion : 1 . Clinically stag IIII , pathologically confirm adenocarcinoma pancreas . Mixed ( e.g . adenosquamous , neuroendocrine feature ) and/or poorly differentiate carcinoma eligible long carcinoma predominantly neuroendocrine carcinoma . Cancers must deem multidisciplinary assessment UVA either Resectable No overt evidence vascular involvement No overt metastatic disease Borderline Resectable , meet one follow category : Local tumor characteristic : Abutment &lt; 180◦ superior mesenteric artery and/or celiac axis Abutment encasement short segment hepatic artery Involvement portal vein superior mesenteric vein amenable vascular reconstruction Concern extra pancreatic metastatic disease indeterminant nodule image Pathologically confirm N1 Borderline performance status medical comorbidities determine investigator concern patient 's ability tolerate pancreatic resection Patients overtly unresectable disease ineligible 2 . No prior therapy pancreatic cancer , include surgery , radiation , chemotherapy 3 . ≥18 year age 4 . Able provide inform consent comply study procedures 5 . Concurrent therapy warfarin permit , INR must check weekly 6 . Concurrent therapy phenytoin permit , phenytoin level must check weekly . 7 . Concurrent therapy CYP2C9 substrates permit discourage . Patients take fluoxetine , glipizide , losartan , voriconazole , CYP2C9 substrates consider switch alternative medication feasible . ( see Appendix 11.3 list CYP2C9 substrates ) . 8 . Adequate organ function : Hematologic ANC ≥ 1.5 x 10^9 cells/liter Plts ≥ 100,000 x 10^9 cells/liter Hepatic Total bilirubin ≤ 5 fold upper limit normal laboratory due biliary obstruction secondary disease . For patient total bilirubin 35 time upper limit , attempt relieve biliary obstruction require AST/ALT ≤ 5 fold upper limit normal laboratory Renal Creatinine clearance measure CockcroftGault ( APPENDIX ) &gt; 30 mL/min . Patients creatinine clearance 3050 mL/min require 25 % reduction capecitabine dose . Exclusion : 1 . No pregnant lactate woman . Women child bear age must negative pregnancy test within seven day begin therapy agree use reliable contraception duration study period . 2 . No comorbid condition deem investigator life expectancy le 6 month 3 . No malignancy diagnose within past 5 year , except situ cancer invasive nonmelanomatous skin cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>Radiation</keyword>
</DOC>